1-2 of 2
Michelle Boyer
Close
Sort by
Journal Articles

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Clinical Trials & Observations
Stephan Stilgenbauer, Eugen Tausch, Andrew W. Roberts, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P. Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T. Ghanim, Michael Moran, Wendy J. Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G. Wierda, John F. Seymour
Journal: Blood Advances
Blood Adv (2024) 8 (8): 1992–2004.
https://doi.org/10.1182/bloodadvances.2023011741
Published: 2024
Includes: Supplemental data
Journal Articles

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Clinical Trials & Observations
Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4553–4557.
https://doi.org/10.1182/bloodadvances.2022007812
Published: 2022